Login to Your Account



Awaiting FDA nod, Vonvendi proves mettle in bleeding disorder

By Marie Powers
News Editor

Monday, August 3, 2015

With a biologics license application for BAX 111 pending at the FDA, investigators for the phase III study of the Baxalta Inc. therapy reported that 100 percent of patients treated with the recombinant, glycosylated von Willebrand factor achieved success in controlling bleeding.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription